Stock 600518 KANGMEI PHARMACEUTICAL CO., LTD.
Add to a list
To use this feature you must be a member
Log inSign up

Kangmei Pharmaceutical Co., Ltd. Share Price

Equities

600518

CNE0000017M1

Pharmaceuticals

End-of-day quote Shanghai S.E.
Other stock markets
 23:00:00 25/04/2024 BST 		5-day change 1st Jan Change
2 CNY +3.63% Intraday chart for Kangmei Pharmaceutical Co., Ltd. +4.71% +7.53%
04-15 Kangmei Pharmaceutical Returns to Profit in 2023; Shares Decline 4% MT
04-12 Kangmei Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023 CI

Financials

Sales 2022 4.18B 577M 46.2B Sales 2023 4.87B 673M 53.87B Capitalization 25.79B 3.56B 285B
Net income 2022 -2.69B -371M -29.72B Net income 2023 103M 14.21M 1.14B EV / Sales 2022 7 x
Net cash position 2022 1.24B 172M 13.74B Net cash position 2023 802M 111M 8.86B EV / Sales 2023 5.13 x
P/E ratio 2022
-11.6 x
P/E ratio 2023
186 x
Employees 4,409
Yield 2022 *
-
Yield 2023
-
Free-Float 67.61%
More Fundamentals * Assessed data

Chart Kangmei Pharmaceutical Co., Ltd.

Dynamic Chart

Latest news about Kangmei Pharmaceutical Co., Ltd.

Kangmei Pharmaceutical Returns to Profit in 2023; Shares Decline 4% MT
Kangmei Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Court Dismisses Winding-Up Petition Against Kangmei Pharma's Unit MT
Kangmei Pharmaceutical Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023 CI
Kangmei Pharmaceutical Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023 CI
Kangmei Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
Kangmei Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2022 CI
Kangmei Pharmaceutical Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2022 CI
Kangmei Pharmaceutical Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2022 CI
China’s Securities Regulator Fines 37 Brokerages Since H1 2019 MT
Kangmei Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2022 CI
Former Kangmei Chairman Loses Appeal Against 12-Year Sentence MT
Kangmei Pharmaceutical Co., Ltd. announced that it has received CNY 6.5 billion in funding from Guangdong Shennong Enterprise Management Partnership (Limited Partnership), GF Securities Co., Ltd., Investment Arm, Wuhu Xintongrui Enterprise Management Center (Limited Partnership), Shenzhen Zhaoping Linghang Investment Center (Limited Partnership), China Resources Shenzhen International Investment Trust Co., Ltd. CI
Kangmei Pharmaceutical Co., Ltd. announced that it expects to receive CNY 6.5 billion in funding from Guangdong Shennong Enterprise Management Partnership (Limited Partnership), GF Securities Co., Ltd., Investment Arm, Wuhu Xintongrui Enterprise Management Center (Limited Partnership), Shenzhen Zhaoping Linghang Investment Center (Limited Partnership), China Resources Shenzhen International Investment Trust Co., Ltd. CI
Kangmei Fraud Case Decision Triggers Exodus of Independent Directors From Listed Firms MT
More news

Quotes and Performance

1 day+3.63%
1 week+4.71%
Current month-7.83%
1 month-6.54%
3 months+5.26%
6 months+6.95%
Current year+7.53%
More quotes

Highs and lows

1 week
1.88
Extreme 1.88
2.01
1 month
1.87
Extreme 1.87
2.21
Current year
1.68
Extreme 1.68
2.33
1 year
1.68
Extreme 1.68
2.50
3 years
1.68
Extreme 1.68
5.16
5 years
1.66
Extreme 1.66
10.90
10 years
1.66
Extreme 1.66
28.25
More quotes

Managers and Directors - Kangmei Pharmaceutical Co., Ltd.

Managers TitleAgeSince
Guo Wei Liu CEO
 Chief Executive Officer 51 09/10/20
Gui Bo Gong DFI
 Director of Finance/CFO 50 09/10/20
Min Li IRC
 Investor Relations Contact 35 31/12/18
Members of the board TitleAgeSince
Xiao Ping Lai BRD
 Director/Board Member 63 29/10/20
Yan Zhu Gao CHM
 Chairman 59 29/10/20
Qi Mi BRD
 Director/Board Member 62 24/01/22
More insiders

ETFs positioned on Kangmei Pharmaceutical Co., Ltd.

Name Weight AuM 1st Jan change Investor Rating
AMUNDI INDEX MSCI EMERGING MARKETS UCITS ETF DR (C) - EUR ETF AMUNDI INDEX MSCI EMERGING MARKETS UCITS ETF DR (C) - EUR
0.00% 2,808 M€ +5.90% -
AMUNDI INDEX MSCI EMERGING MARKETS UCITS ETF DR (D) - EUR ETF AMUNDI INDEX MSCI EMERGING MARKETS UCITS ETF DR (D) - EUR
0.00% 441 M€ +4.60% -
AMUNDI INDEX MSCI EMERGING MARKETS UCITS ETF - USD ETF AMUNDI INDEX MSCI EMERGING MARKETS UCITS ETF - USD
0.00% 149 M€ +2.17% -
More ETFs positioned on Kangmei Pharmaceutical Co., Ltd.

Quotes

Date Price Change Volume
26/04/24 2 +3.63% 124,124,600
25/04/24 1.93 +1.05% 71,698,460
24/04/24 1.91 -0.52% 51,835,270
23/04/24 1.92 +1.05% 77,977,420
22/04/24 1.9 -0.52% 68,141,810

End-of-day quote Shanghai S.E., April 25, 2024

More quotes

Company Profile

Kangmei Pharmaceutical Co., Ltd. develops, produces, and sells pharmaceutical products intended primarily for treating hypertension and colds. The group offers Chinese medications (ginseng, salvia, codonopsis, etc.) and chemical medications (clarithromycin, doxazosin mesylate, paracetamol, etc.). All sales are earned in China.
Sector
Pharmaceuticals
Calendar
29/04/2024 - Q1 2024 Earnings Release
More about the company

Income Statement Evolution

More financial data

Annual profits - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

1st Jan change Capi.
KANGMEI PHARMACEUTICAL CO., LTD. Stock Kangmei Pharmaceutical Co., Ltd.
+7.53% 3.83B
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+25.83% 661B
NOVO NORDISK A/S Stock Novo Nordisk A/S
+27.00% 566B
JOHNSON & JOHNSON Stock Johnson & Johnson
-6.76% 352B
MERCK & CO., INC. Stock Merck & Co., Inc.
+20.34% 332B
ABBVIE INC. Stock AbbVie Inc.
+3.00% 283B
ASTRAZENECA PLC Stock AstraZeneca PLC
+13.09% 231B
NOVARTIS AG Stock Novartis AG
+5.46% 200B
ROCHE HOLDING AG Stock Roche Holding AG
-9.61% 195B
AMGEN INC. Stock Amgen Inc.
-6.26% 145B
Other Pharmaceuticals
  1. Stock Market
  2. Equities
  3. 600518 Stock